Comparative Pharmacology
Head-to-head clinical analysis: ENZEEVU versus EOVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENZEEVU versus EOVIST.
ENZEEVU vs EOVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enzeevu (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor. It acts as a soluble decoy receptor that binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing their interaction with cell surface receptors (VEGFR1 and VEGFR2), reducing angiogenesis and vascular permeability.
Gadoxetic acid is a hepatocyte-specific MRI contrast agent. It is taken up by hepatocytes via organic anion transporting polypeptides (OATP1B1 and OATP1B3) and excreted into bile via multidrug resistance-associated protein 2 (MRP2). The paramagnetic gadolinium ion shortens T1 relaxation time, enhancing signal intensity in liver tissue on T1-weighted images.
200 mg subcutaneously every 4 weeks
0.1 mL/kg body weight (0.025 mmol Gd/kg) intravenously as a bolus injection, followed by a saline flush of at least 5 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10-14 hours) in healthy adults. This supports once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life is approximately 1.5 hours (range 1.2–1.8 h) in patients with normal renal function; half-life is prolonged in renal impairment, correlating with glomerular filtration rate.
Primarily renal excretion as unchanged drug (approximately 70%) and fecal excretion (approximately 20%) after intravenous administration. Biliary excretion is minor (<10%).
Primarily renal elimination: 95% of the administered dose is excreted unchanged in urine within 72 hours; less than 1% eliminated via biliary/fecal route.
Category C
Category C
Diagnostic Imaging Contrast Agent
Diagnostic Imaging Contrast Agent